Utility of synthetic MRI in distinguish benign and malignant breast lesions and further in predicting the expression status of immunohistochemistry markers in breast cancer

Author:

Li Xiaojun1,Fan Zhichang2,Jiang Hongnan1,Niu Jinliang3,Bian Wenjin2,Wang Chen3,Wang Ying3,Zhang Runmei3,Zhang Hui2

Affiliation:

1. Cancer Hospital of Chinese Academy of Medical Sciences

2. Shanxi Medical University

3. Second Hospital of Shanxi Medical University

Abstract

Abstract Objective To evaluate and compare the performance of synthetic magnetic resonance imaging (SyMRI) in classifying benign and malignant breast lesions and predicting the expression status of immunohistochemistry (IHC) markers.Methods We retrospectively analysed 121 patients with breast lesions who underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and SyMRI before surgery in our hospital. DCE-MRI was used to assess the lesions, and then regions of interest (ROIs) were outlined on SyMRI (before and after enhancement), and apparent diffusion coefficient (ADC) maps to obtain quantitative values. After being grouped according to benign and malignant status, the breast lesions were divided into high and low expression groups according to the expression status of IHC markers. Logistic regression was used to analyse the differences in independent variables between groups. The performance of the modalities in classification and prediction was evaluated by receiver operating characteristic (ROC) curves.Results In total, 57 of 121 lesions were benign, and the other 64 were malignant. Quantitative values from proton density-weighted imaging prior to an injection of the contrast agent (PD-Pre) and T2-weighted imaging (T2WI) after the injection (T2-Gd), as well as its standard deviation (SD of T2-Gd), were valuable SyMRI parameters for the classification of benign and malignant breast lesions, but the performance of SyMRI (area under the curve, AUC=0.716) was not as good as that of ADC values (AUC=0.853). However, ADC values could not predict the expression status of breast cancer markers, for which SyMRI had excellent performance. The AUCs of androgen receptor (AR), oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), p53 and Ki-63 were 0.687, 0.890, 0.852, 0.746, 0.813 and 0.774, respectively.Conclusions SyMRI had certain value in distinguishing between benign and malignant breast lesions, and ADC values were still the ideal method. However, to predict the expression status of IHC markers, SyMRI had an incomparable value compared with ADC values.

Publisher

Research Square Platform LLC

Reference45 articles.

1. Hyuna Sung, Jacques Ferlay, Rebecca L Siegal, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71:209–249.

2. Clinical management of breast cancer heterogeneity;Zardavas D;Nat Rev Clin Oncol,2015

3. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets;Liang Y;Semin Cancer Biol,2020

4. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review;Kono M;JAMA Oncol,2017

5. Comparative Analysis of Amide Proton Transfer MRI and Diffusion-Weighted Imaging in Assessing p53 and Ki-67 Expression of Rectal Adenocarcinoma;Li L;J Magn Reson Imaging,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3